. Author manuscript; available in PMC: 2011 May 1.

Published in final edited form as: Am J Cardiol. 2010 Mar 20;105(9):1289–1296. doi: 10.1016/j.amjcard.2009.12.051

Table 2.

Meta-Regression^* for Coronary Heart Disease or Death as a Function of Lipid Measures or Trial Duration

	RCTs w/o Active Comparator		All RCTs
	β per SD^† Increase	P	β per SD^‡ Increase	P
Coronary Heart Disease
LnOR_{Coronary Heart Disease}
Baseline LDL_Rx	−0.045	0.320	−0.083	0.014
ΔLDL_{Baseline-Final}	−0.091	0.052	−0.082	0.029
%ΔLDL_{Baseline-Final}	−0.063	0.221	−0.062	0.143
ΔLDL_Control-Rx	−0.108	<0.001	−0.129	<0.001
%ΔLDL_Control-Rx	−0.095	0.030	−0.127	<0.001
Trial Duration	0.011	0.813	0.052	0.237
All-cause Mortality
LnOR_Mortality
Baseline LDL_Rx	−0.065	0.081	−0.067	0.022
ΔLDL_{Baseline-Final}	−0.018	0.686	−0.021	0.511
%ΔLDL_{Baseline-Final}	0.020	0.581	0.002	0.941
ΔLDL_Control-Rx	−0.030	0.397	−0.055	0.041
%ΔLDL_Control-Rx	0	0.993	−0.030	0.297
Trial Duration	−0.018	0.585	0.012	0.702

Models are univariable, i.e., the β coefficients refer to the relationship with each measure as a single independent variable.

^†

SD (RCTs w/o Active Comparator): Baseline LDL_Rx = 24 mg/dL; ΔLDL_{Baseline-Final} = 15 mg/dL ; %ΔLDL_{Baseline-Final} = 10%; = ΔLDL_Control-Rx = 16 mg/dL ; %ΔLDL_Control-Rx = 11%; Trial Duration = 15 months.

^‡

SD (All RCTs): Baseline LDL_Rx = 25 mg/dL; ΔLDL_{Baseline-Final} = 17 mg/dL; %ΔLDL_{Baseline-Final} = 11%; ΔLDL_Control-Rx = 17 mg/dL; %ΔLDL_Control-Rx = 11%; Trial Duration = 23 months.

Ln = Natural logarithm. OR = Odds Ratio. RCT = Randomized Controlled Trial. SD = Standard Deviation.